Healthcare Industry News: HSMN NewsFeed
News Release - January 3, 2019
Roswell Biotechnologies Secures $32 Million Series A Financing RoundHarnessing the Power of Molecular Electronics to Revolutionize DNA Sequencing
SAN DIEGO, Jan. 3, 2019 -- (Healthcare Sales & Marketing Network) -- Roswell Biotechnologies, Inc., the pioneer in the development of a molecular electronics platform for DNA Sequencing, has closed a $32 million round of Series A financing backed by multiple investors. Proceeds from the financing will support the development of their disruptive DNA sequencing Molecular Electronics technology.
"The capital raised will fuel the company's R&D, expanding our operations to full strength for our programs in sensors, chips, instruments and applications. We are on an aggressive path to realizing the $100, 1-hour, clinical grade genome, to unlock the promise of Precision Medicine and usher in the DNA economy," said Paul Mola, President and CEO of Roswell.
Roswell has developed a revolutionary process to integrate molecules into electronic circuits creating potential for unprecedented performance and scalability. The company's platform enables direct real-time monitoring of polymerase activity that has been integrated into a nano-circuit for DNA Sequencing. The company has created a nano-scale molecular electronic sensor for reading DNA that can be deployed as a massively parallel sensor array on a standard CMOS chip.
"Our intent in founding Roswell was to create an 'Endgame' Sequencing technology: highly disruptive now, and with a long future road-map of improvement," said CSO Dr. Barry Merriman. "Only true molecular electronics can deliver the disruptive $100, 1-hour genome in the near term, combined with a long-term road-map to much lower price points and greater speeds."
Commenting on the company's achievements, Dr. James Tour, Professor of Chemistry at Rice University, and an early pioneer in the field of molecular electronics said, "It is indeed a thrill to see a molecular electronics platform being used to get to the heart of the greatest molecular challenge in the constitution of humankind: the code of the human genome. Roswell's solution has the promise of being accessible to the entire human race due to the process simplicity and accessible cost."
About Roswell Biotechnologies
Roswell Biotechnologies is a life science startup focused on innovative DNA reading technologies for the research, drug discovery, and diagnostic markets. The Company's technology is based on the most recent advances in CMOS chips and molecular electronic biosensors, applied to overcome major challenges in the adoption of Precision Medicine.
Source: Roswell Biotechnologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.